Kymera Therapeutics (KYMR) Stock Jumps As Q3 Results Show Zero Revenue

Kymera Therapeutics just dropped Q3 2026 numbers and the share price jumped 3.3% to US$126.63. Traders cheered first and asked questions later. The headline result was stark. The biotech reported zero revenue for the quarter and a loss of US$132.0 million, a sharp squeeze for a story that has been leaning on partnership and collaboration income.

Short term momentum looks upbeat after a 7 day gain of about 0.1%, which turned into a stronger move today. The emotional push is all about pipeline optimism, while the financial reality points straight at a widening earnings hit.

Love the pipeline story at Kymera Therapeutics but worried about zero revenue and a US$132.0 million quarterly loss? Filter for biotechs with stronger funding and cash discipline using the list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$0 million vs. US$2.764 million (shift to no reported revenue in the current quarter)
• Net Loss (Q3 2026 vs Q3 2025): US$132.0 million loss vs. US$82.175 million loss (wider quarterly loss)
• Basic EPS (Q3 2026 vs Q3 2025): loss of US$1.32 per share vs. loss of US$0.94 per share (larger loss per share)
• R&D and G&A Spend (Q3 2026): R&D US$128.5 million and G&A US$18.7 million, with a significant portion of expense concentrated in research activity

Kymera says its cash runway stretches all the way to 2029. Ask Charlie what Kymera’s cash runway to 2029 really enables.

Kymera bull case leans hard on execution

Optimists argue Kymera can turn today’s pipeline into a broad commercial engine.

"Bullish analysts expect Kymera Therapeutics to turn KT-621, KT-579 and partnered degraders into a broad oral immunology and targeted protein degradation portfolio, supported by a cash runway that management guides into 2029."

Q3 confirms some building blocks. KT-579 cleared first clinical testing with strong target knockdown and clean safety. KT-621 has completed the placebo controlled phase of BROADEN-2 and moved 98% of eligible patients into long term follow up, which supports durability work ahead. Partnerships are progressing with KT-485 and KT-200 moving forward. The flip side is simple. Kymera booked no Q3 revenue and reported a US$132.0 million loss, so the financial proof of that broad portfolio thesis has not arrived yet.

Bear case zeroes in on funding and control

On the risk side, the concern is that governance and external funding could undercut execution just when Kymera needs capital the most.

"Two ongoing shareholder investigations into potential fiduciary breaches by Kymera Therapeutics directors create governance uncertainty."

That risk now meets a quarter with no collaboration income and heavy R&D and G&A spend of roughly US$147.2 million combined. Management still points to about US$1.6b in cash and a runway into 2029, which helps offset near term pressure. The share price gain of 3.3% after Q3 suggests investors are currently giving more weight to clinical milestones than to the governance overhang, but the investigations and funding reliance remain active constraints on the story.

The price and this Narrative do not agree. → Uncover what this Narrative says Kymera Therapeutics is actually worth.

Hunt For Mispriced Execution Stories

Kymera Therapeutics just showed how clinical optimism can move faster than the income statement. The real opportunity is finding stocks that could be undervalued before the market closes that gap.

• Company 1 - 48% below our estimate - converts a record project backlog into long dated data center and modular construction work tied to AI buildouts.
• Company 2 - 42% below our estimate - sells integrated data center systems as customers shift from piecemeal servers to full AI focused infrastructure solutions.
• Company 3 - 38% below our estimate - expands protective film manufacturing and installation capacity to serve rising high margin dealership and OEM channel demand.

Those are three of them. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com